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ABSTRACT
BACKGROUND Financial toxicity (FT) is a well-established side-effect of the high costs associated with cancer care. In
recent years, studies have suggested that a signiﬁcant proportion of those with atherosclerotic cardiovascular disease
(ASCVD) experience FT and its consequences.
OBJECTIVES This study aimed to compare FT for individuals with neither ASCVD nor cancer, ASCVD only, cancer only,
and both ASCVD and cancer.
METHODS From the National Health Interview Survey, we identiﬁed adults with self-reported ASCVD and/or cancer
between 2013 and 2018, stratifying results by nonelderly (age <65 years) and elderly (age $65 years). We deﬁned FT if
any of the following were present: any difﬁculty paying medical bills, high ﬁnancial distress, cost-related medication
nonadherence, food insecurity, and/or foregone/delayed care due to cost.
RESULTS The prevalence of FT was higher among those with ASCVD when compared with cancer (54% vs. 41%; p <
0.001). When studying the individual components of FT, in adjusted analyses, those with ASCVD had higher odds of any
difﬁculty paying medical bills (odds ratio [OR]: 1.22; 95% conﬁdence interval [CI]: 1.09 to 1.36), inability to pay bills (OR:
1.25; 95% CI: 1.04 to 1.50), cost-related medication nonadherence (OR: 1.28; 95% CI: 1.08 to 1.51), food insecurity (OR:
1.39; 95% CI: 1.17 to 1.64), and foregone/delayed care due to cost (OR: 1.17; 95% CI: 1.01 to 1.36). The presence of $3 of
these factors was signiﬁcantly higher among those with ASCVD and those with both ASCVD and cancer when compared with
those with cancer (23% vs. 30% vs. 13%, respectively; p < 0.001). These results remained similar in the elderly population.
CONCLUSIONS Our study highlights that FT is greater among patients with ASCVD compared with those with
cancer, with the highest burden among those with both conditions. (J Am Coll Cardiol CardioOnc 2021;3:236–46)
© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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F

inancial toxicity (FT) refers to the ﬁnancial

METHODS

ABBREVIATIONS
AND ACRONYMS

strain that patients experience while accessing
health care, and has been widely researched in

STUDY DESIGN. We utilized 6 years of data

cancer patients (1). Used interchangeably with “ﬁnan-

(2013 to 2018) from the NHIS (National Health

ASCVD = atherosclerotic
cardiovascular disease

cial hardship,” “ﬁnancial (di)stress,” “(high) ﬁnancial

Interview Survey). The NHIS, a database

burden,” “economic burden,” and “economic hard-

compiled by the National Center for Health

ship” (2), it has been reported that a large proportion

Statistics/Center for Disease Control and

of patients with cancer experience FT (3–5). This

Prevention,

afﬂiction is not limited to cancer diagnosis, but also

cross-sectional national surveys that incor-

manifests as the impaired health of patients following

porate complex, multistage sampling to pro-

factor

treatment and survivorship (6). These insights have

vide estimates on the noninstitutionalized

FT = ﬁnancial toxicity

also been directed toward implementation of FT-

U.S. population (21). The NHIS questionnaire

speciﬁc interventions for better screening, social sup-

is divided into 4 core components: House-

port, and care for patients with cancer (7–10).

hold Composition, Family Core, Sample Child

is

constructed

from

annual,

BMI = body mass index
CI = conﬁdence interval
COST = Comprehensive Score
for Financial Toxicity

CRF = cardiovascular risk

OOP = out-of-pocket
OR = odds ratios

Although there has been an emphasis on under-

Core, and Sample Adult Core (21). The Household

standing and remedying FT in patients with cancer

Composition ﬁle collects basic information and rela-

(3),

less

tionship information about all persons in a house-

frequently among patients with atherosclerotic car-

hold. The Family Core ﬁle collects sociodemographic

diovascular disease (ASCVD). The extent of FT and

characteristics, basic indicators of health status, ac-

how it manifests might differ between patients with

tivity limitations, injuries, health insurance coverage,

ASCVD and cancer. For example, patients with cancer

and access to, and utilization of, health care services.

may have short bursts of high expenditures with

From each family, 1 sample child and 1 sample adult

chemotherapy, whereas ASCVD incurs a more chronic

are randomly selected to gather more detailed infor-

economic burden related to the costs of drugs, pro-

mation. This study utilized the Sample Adult Core

cedures, clinician visits, and hospital stays (11). The

ﬁles (with relevant variables added from the Family

economic burden that ASCVD confers to patients and

Core

families who experience it has been described in the

mographic and socioeconomic characteristics, health

this

phenomenon
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has

been

studied

ﬁles),

which

are

supplemented

with

de-

last few years (12–15). Additionally, with prolonged

status, health care services, and health-related be-

survival following the diagnosis of cancer, the cardiac

haviors on the U.S. adult population (21). Because

toxicity of some treatments, and better treatment

NHIS data are publicly available and deidentiﬁed, this

options for ASCVD, the population of patients with

study was exempt from institutional review board

simultaneous ASCVD and cancer is growing. Without

approval (22).

the ability to pay, patients can experience ﬁnancial
health and non–health-related difﬁculties, such as

STUDY POPULATION. We used a self-reported diag-

difﬁculty paying medical bills, ﬁnancial distress, cost-

nosis of coronary or cerebrovascular disease to iden-

related medication nonadherence, and food insecu-

tify patients with ASCVD. Speciﬁcally, individuals

rity, and may forego or delay care due to cost (16–19).

were included if they reported having coronary artery

However, no studies to date have contrasted the FT

disease (“yes” to any of the following 3 questions:

incurred in patients with ASCVD and/or cancer, which

“Have you ever been told by a doctor or other health

are currently the 2 leading causes of death in the

professional that you had.coronary heart disease,”

United States (20). The current study, using a na-

“.angina, also called angina pectoris,” or “.a heart

tionally representative sample of the United States,

attack [also called myocardial infarction]?”) and/or

compared the ﬁnancial burden of health care on adult

stroke (“yes” to the following question: “Have you

patients with neither ASCVD nor cancer, ASCVD only,

ever been told by a doctor or other health professional

cancer only, and both ASCVD and cancer.

that you had a stroke?”) were classiﬁed as having

University, College Station, Texas, USA; lDepartment of Health Policy and Management, Yale School of Public Health, New Haven,
Connecticut, USA; mCancer Center, Houston Methodist Research Institute, Houston, Texas, USA; and the nDepartment of Surgical
Oncology, Fox Chase Cancer Center-Temple Health, Philadelphia, Pennsylvania, USA. *Dr. Valero-Elizondo and Mr. Chouairi
contributed equally to this work.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’
institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information,
visit the Author Center.
Manuscript received December 7, 2020; accepted February 12, 2021.
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ASCVD. Similarly, individuals that answered “yes” to

An aggregate score was created, ranging from 6 to 24,

the question, “Have you ever been told by a doctor or

a higher score indicating increased levels of ﬁnancial

other health professional that you had cancer or a

distress (26). Participants within the highest quartile

malignancy of any kind?” were classiﬁed as having

were designated as experiencing high levels of

cancer. These methods of diagnosis ascertainment

ﬁnancial distress.

have been used in previous literature (12,23). For our

Cost-related

main analyses, we included only non-elderly ($18

related medication nonadherence was deﬁned as a

to <65 years of age) adults to capture the population

survey responder reporting any of the following be-

without universal ﬁnancial protections from public

haviors to save money in the last 12 months: skipping

insurance. As a subanalysis, we further extended our

medication doses, taking less medicine, or delaying

medication

n o n a d h e r e n c e . Cost-

study population to elderly ($65 years of age) adults.

ﬁlling a prescription (Supplemental Table 1).

STUDY

the

F o o d i n s e c u r i t y . Food security in the last 30 days

purposes of this paper, we deﬁned FT as having any

was created based on the 10-item questionnaire as

of the following: difﬁculty paying medical bills,

recommended by the U.S. Department of Agriculture

inability to pay them at all, high ﬁnancial distress,

Economic Research Service (Supplemental Table 1)

cost-related

food

(27,28), and constructed per the NHIS instructions

insecurity, and/or delayed/foregone care due to

(28). In questions about frequency of occurrence in

OUTCOMES. F i n a n c i a l

medication

t o x i c i t y . For

nonadherence,

cost. The speciﬁc questions and deﬁnitions for each

the past 30 days, answers of $ 3 days were considered

FT component are presented in Supplemental Table 1.

afﬁrmative. A raw score ranging from 0 to 10 was

D i f ﬁ c u l t y p a y i n g m e d i c a l b i l l s . The following

calculated, with the following categories: food secure

questions were used to assess the study population

(score 0 to 2), low food security (score 3 to 5), and very

having “any difﬁculty paying medical bills”:

low food security (score 6 to 10). For this study’s

 “In the past 12 months, did you/anyone in your

purposes, food insecurity included those who had
either low or very low food security, as is common in

family have problems paying or were unable to pay

practice (29).

any medical bills? Include bills for doctors, dentists,

Delayed/foregone

hospitals,

and/or foregone care due to cost was assessed by

therapists,

medication,

equipment,

nursing home or home care,” or
 “Do you/anyone in your family currently have any

care

due

to

c o s t . Delayed

asking individuals whether, within the past year,
medical care had been delayed due to cost, or if they

medical bills that are being paid off over time? This

needed but did not receive medical care due to cost

could include medical bills being paid off with a

(30).

credit card, through personal loans, or bill paying
arrangements with hospitals or other providers. The
bills can be from earlier years as well as this year.”

COVARIATES. Other

covariates

included

in

this

study were age, sex, race/ethnicity, family income,
education, insurance status, region, cardiovascular

This approach has been previously employed in

risk factor (CRF) proﬁle, number of chronic comor-

other studies and surveys (24,25). Additionally, for

bidities, and for individuals with cancer, years since

individuals who answered “yes” to having difﬁculty

diagnosis. Categorical variables were classiﬁed as

paying bills, a follow-up question was asked: “Do you/

follows: 2 categories for sex; 3 categories for race/

does anyone in your family currently have any medical

ethnicity (non-Hispanic White, non-Hispanic Black,

bills that you are unable to pay at all?” Individuals

and Hispanic); 2 categories for family income (based

who answered “yes” to this question were studied as

on percent of family income to the federal poverty

a separate group—those who were “unable to pay bills

limit from the Census Bureau: high/middle-income

at all.”

[$200%], low-income [<200%]); 2 categories for edﬁnancial

d i s t r e s s . Financial distress was

ucation (some college or higher, high school/GED or

derived from 6 questions regarding the level of

less than high school); 2 categories for insurance

concern with several ﬁnancial matters, including:

status (insured, uninsured), and 4 categories for

lack of retirement funds, ability to pay medical costs

geographic region (Northeast, Midwest, South, and

of serious illness, maintaining an acceptable quality

West). CRF proﬁle was calculated by determining, via

of living, ability to pay day-to-day health care costs,

self-report, whether individuals had 1 or more of the

inability to pay monthly bills, and inability to pay

following: diagnosis of hypertension, diabetes melli-

rent/mortgage/housing costs (Supplemental Table 1).

tus or high cholesterol, obesity (calculated body mass

The questions were responded to on a 4-point scale,

index $30 kg/m 2), current smoker, or insufﬁcient

ranging from “not worried at all” to “very worried.”

physical activity (based on not participating in >150

High
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min/week of moderate-intensity aerobic physical ac-

analyses, p < 0.05 was considered statistically sig-

tivity, >75 min/week of vigorous-intensity aerobic

niﬁcant. All analyses were carried out using Stata

physical activity, or a total combination of $150 min/

version 16 (StataCorp, LP, College Station, Texas). All

week of moderate/vigorous-intensity aerobic physical

analyses were survey-speciﬁc considering the com-

activity). Based on the presence of these individual

plex design of the NHIS survey.

risk factors, individuals were categorized as “poor”
($4 CRFs), “average” (2 to 3 CRFs), and “optimal” (0
to 1 CRF) (31,32). Self-reported chronic comorbidities,
including emphysema, chronic obstructive pulmonary disease, asthma, gastrointestinal ulcer, arthritis
(including arthritis, gout, ﬁbromyalgia, rheumatoid
arthritis, and systemic lupus erythematosus), any
kind of liver condition, or “weak/failing” kidneys,
were aggregated, and categorized as having 0, 1,
or $2. For individuals with cancer, time since diagnosis was measured in years, and presented as both
continuous, and categorized as $0 to #5, >5 to #15,
and >15 years.

RESULTS
NON-ELDERLY POPULATION. From 2013 to 2018, the

NHIS total sample of non-elderly ($18 to <65 years of
age) adults was 141,826, of which 6,887 (weighted
prevalence: 4.5% [95% CI: 4.4% to 4.7%]), 6,093
(weighted prevalence: 3.8% [95% CI: 3.7% to 4.0%]),
and 971 (weighted prevalence: 0.6% [95% CI: 0.56% to
0.65%]) had cancer, ASCVD, and both ASCVD and
cancer, respectively. This translates to 8.9, 7.5, and
1.2 million non-elderly U.S. adults yearly, respectively (Table 1).
Most individuals in the non-elderly population

STATISTICAL ANALYSIS. Chi-square tests were used

were 40 to 64 years of age, insured, and White.

to compare categorical variables, and weighted pro-

Women were more likely to report having cancer,

portions were used to study prevalence. Continuous

with a majority coming from middle-/high-income

variables were reported as medians with interquartile

households and with a higher education level. In

range. Categorical variables were reported as un-

contrast, those reporting ASCVD (with or without

weighted counts with their accompanying weighted

cancer) were evenly distributed by sex, education,

proportions (in tables), and as weighted proportions

and income levels, although with a shift toward a

with 95% conﬁdence interval (CI) (in ﬁgures).

more unfavorable CRF proﬁle (Table 1). Among the

Further, we used linear regression to test for linear

non-elderly adults with cancer, the most frequently

trends of the prevalence of FT measures between

reported

disease groups. Unadjusted and adjusted logistic

breast, cervix, prostate, and “other” (Supplemental

regression models were used to measure the associ-

Table 2). Similar patterns were observed in the pop-

ation between FT prevalence and disease group

ulation that reported both ASCVD and cancer.

cancers

included

skin

(nonmelanoma),

(neither ASCVD nor cancer, ASCVD, cancer, or both

Prevalence of FT measures by underlying condi-

ASCVD and cancer), and were reported as odds ratios

tion are comprehensively depicted in our Central

(ORs) with 95% CIs. Adjusted models included vari-

Illustration. Any FT was present to a higher extent

ables that have been correlated with presence and/or

across disease categories from neither ASCVD nor

risk for FT (e.g., income and insurance status), or that

cancer (38.3% [95% CI: 37.8% to 38.9%]), to cancer

are clinically signiﬁcant (e.g., age, cardiovascular risk

(41.0% [95% CI: 39.5% to 42.6%]), to ASCVD (54.1%

factors, and comorbidities). We used the Akaike In-

[95% CI: 52.4% to 55.8%]), and both (ASCVD and

formation Criterion to determine the optimal vari-

cancer;

ables to include in our adjusted model. The full list of

trend <0.001) (Central Illustration). Difﬁculty paying

explanatory

variables

included

age,

sex,

54.5%

[95%

CI:

50.3%

to

58.7%])

(p

race/

medical bills was signiﬁcantly higher for individuals

ethnicity, family income, education, insurance sta-

with ASCVD (with or without cancer; 44.8% [95% CI:

tus, geographic region, cardiovascular risk factor

43.1% to 46.5%] and 47.4% [95% CI: 43.1% to 51.7%],

proﬁle, and comorbidities for all outcome measures;

respectively) when compared with those with cancer

in the case of high ﬁnancial distress, cost-related

(35.0% [95% CI: 33.5% to 36.6%]). When analyzing

medication nonadherence, food insecurity, and fore-

those with the highest burden from medical bills—

gone/delayed care due to cost, burden from medical

those with an inability to pay bills at all—a statistically

bills was also included due to the risk of confounding.

signiﬁcant trend was also seen when comparing

Similar models were constructed for the individual

cancer (10.1% [95% CI: 9.0% to 11.3%]) versus ASCVD

components of FT. Variance estimation for the entire

(18.2% [95% CI: 16.9% to 19.5%]) versus both (23.2%

pooled cohort was obtained from the Integrated

[95% CI: 19.8% to 26.8%]) (p trend <0.001). Overall,

Public Use Microdata Series (33). For all statistical

the same pattern (i.e., ASCVD and cancer > ASCVD >
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T A B L E 1 General Characteristics Among Non-Elderly Adults With Cancer and/or ASCVD,

From the National Health Interview Survey, 2013 to 2018

further observed in all of FT measures: any difﬁculty
paying medical bills (OR: 2.27; 95% CI: 1.91 to 2.70),
inability to pay medical bills at all (OR: 3.43; 95% CI:

Neither ASCVD
Nor Cancer

Cancer
Only

ASCVD
Only

Both ASCVD
and Cancer

2.83 to 4.16), high ﬁnancial distress (OR: 2.46; 95% CI:

127,875

6,887

6,093

971

2.08 to 2.92), cost-related medication nonadherence

178,640,421
(91.1)

8,865,357
(4.5)

7,493,768
(3.8)

1,173,167
(0.6)

18–39

61,680 (50.7)

979 (14.3)

717 (13.3)

66 (7.8)

40–64

66,195 (49.3)

5,908 (85.7)

5,376 (86.7)

905 (92.2)

Male

59,431 (49.3)

2,350 (36.2)

3,390 (59.1)

441 (48.7)

cancer was associated with an increased odds for all

Female

68,444 (50.7)

4,537 (63.8)

2,703 (40.9)

530 (51.3)

FT measures when compared with individuals with

Non-Hispanic White

78,011 (61.7)

5,626 (83.6)

3,801 (64.9)

762 (82.1)

multivariable

Non-Hispanic Black

17,463 (13.2)

503 (6.4)

1,146 (17.1)

105 (9.3)

founders including variables such as family income

Sample
Weighted sample
Age category, yrs

(OR: 4.72; 95% CI: 3.86 to 5.78), food insecurity (OR:
3.19; 95% CI: 2.65 to 3.83), and foregone/delayed care
due to cost (OR: 2.51; 95% CI: 2.08 to 3.03) when

Sex

compared with patients who reported neither disease
(Table 2). The presence of ASCVD with or without

cancer, as evidenced by nonoverlapping CIs. In

Race/ethnicity

Non-Hispanic Asian

analysis,

after

adjusting

for

con-

8,184 (6.6)

155 (2.5)

177 (3.3)

6 (0.5)

22,416 (18.4)

526 (7.5)

838 (14.8)

72 (8.1)

Middle/high income

77,946 (69.5)

4,658 (77.9)

2,724 (54.1)

424 (54.3)

signiﬁcant: those with ASCVD and cancer had

Low income

42,332 (30.5)

1,826 (22.1)

3,059 (45.9)

497 (45.7)

increased odds of being unable to pay medical bills at

Some college or higher

82,769 (64.6)

4,777 (70.4)

2,993 (50.2)

543 (56.8)

nonadherence, and foregone/delayed medical care,

HS/GED or less than HS

44,652 (35.4)

2,094 (29.6)

3,076 (49.8)

425 (43.2)

when compared with those with cancer (Table 2). Of

107,418 (85.3)

6,327 (92.9)

5,335 (87.9)

887 (91.7)

19,816 (14.7)

544 (7.1)

740 (12.1)

79 (8.3)

Northeast

20,323 (17.4)

1,120 (17.3)

894 (15.1)

141 (15.8)

cancer in adjusted analyses (interaction p ¼ 0.39). Our

Midwest

27,750 (22.2)

1,602 (23.6)

1,344 (23.6)

213 (24.1)

ﬁndings further reinforce the notion that presence of

South

45,443 (36.3)

2,379 (37.2)

2,566 (42.7)

415 (43.0)

ASCVD was a key determinant of the presence and

West

34,359 (24.0)

1,786 (22.0)

1,289 (18.6)

202 (17.0)

severity of FT.

Optimal

73,456 (61.2)

2,952 (47.4)

940 (17.9)

142 (16.5)

Average

41,420 (32.8)

2,789 (41.2)

2,637 (45.6)

390 (45.2)

FT measures each individual had, we found that the

8,187 (6.0)

819 (11.3)

2,131 (36.4)

360 (38.3)

Hispanic
Family income

and insurance status, the effect sizes were attenuated
but associations remained consistent and statistically

all, high ﬁnancial distress, cost-related medication

Education

Insurance status

note, even though effect sizes were larger (i.e., higher

Insured
Uninsured
Region

CRF proﬁle

ORs), there were no statistical differences between
the groups with ASCVD only and both ASCVD and

Furthermore, in a composite score of number of

Poor
Comorbidities

prevalence of having $3 was 9% (z17.2 million)
among

those

with

neither

disease,

13%

0

88,643 (70.8)

3,203 (48.3)

2,149 (37.9)

210 (25.0)

(z25.3 million) among those with cancer, 23%

1

29,926 (22.7)

2,259 (32.8)

1,950 (32.5)

270 (28.6)

(z44.5 million) among those with ASCVD, and 30%

9,306 (6.5)

1,425 (18.9)

1,994 (29.6)

491 (46.4)

(z57.9

—

6 (2–14)

—

7 (2–16)

$2
Years since cancer diagnosis

million)

among

those

with

both

(p

trend <0.001) (Figure 1).

Years since cancer diagnosis
0 to #5

—

2,989 (44.7)

—

400 (41.6)

ELDERLY POPULATION. From 2013 to 2018, the NHIS

>5 to #15

—

2,336 (33.8)

—

287 (31.6)

total sample of elderly ($65 years of age) adults was

>15

—

1,562 (21.5)

—

284 (26.8)

48,287, of which 8,457 (weighted prevalence: 18.1%

Values are n, n (%), or median (interquartile range). All p values for comparison between groups were <0.001.
ASCVD ¼ atherosclerotic cardiovascular disease; CRF ¼ cardiovascular risk factor; GED ¼ general equivalency
diploma; HS ¼ high school.

[95% CI: 17.7% to 18.6%]), 8,167 (weighted prevalence: 16.9% [95% CI: 16.4% to 17.3%]), and 3,211
(weighted prevalence: 6.8% [95% CI: 6.5% to 7.1%])
had cancer, ASCVD, and both, respectively. This
translates to 8.6, 8.0, and 3.2 million elderly U.S.

cancer > neither) was observed for high ﬁnancial

adults yearly (Supplemental Table 3). Virtually all

distress, cost-related medication nonadherence, food

patients in this age category were White and insured,

insecurity, and delayed/foregone medical care due to

and the majority were from middle/high-income

cost when comparing those reporting ASCVD (with or

households. Individuals with ASCVD (regardless of

without cancer) versus cancer (all p trend <0.001).

cancer diagnosis) were more likely to be men,

In univariable logistic regression analysis, patients

whereas older adults (age $75 years) were more likely

with both cancer and ASCVD had increased odds of

to have combined ASCVD and cancer diagnoses.

any FT (OR: 1.93; 95% CI: 1.63 to 2.28). This was

Among the elderly adults with cancer, the most
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C ENTR AL I LL U STRA T I O N Prevalence of Financial Toxicity Measures by Cancer and/or ASCVD
Status, Among Non-Elderly Adults, From the National Health Interview Survey, 2013 to 2018

Valero-Elizondo, J. et al. J Am Coll Cardiol CardioOnc. 2021;3(2):236–46.

Any ﬁnancial toxicity: any difﬁculty paying medical bills  unable to pay bills at all  high ﬁnancial distress  cost-related medication nonadherence  food insecurity  delayed/foregone care due to cost. The p value for linear trends was <0.001 for all ﬁnancial toxicity
prevalence measures when comparing disease groups. Data in this ﬁgure represents weighted prevalence (bars) with 95% conﬁdence interval
(error bars). ASCVD ¼ atherosclerotic cardiovascular disease; NHIS ¼ National Health Interview Survey.
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T A B L E 2 Burden of Financial Toxicity Among Non-Elderly Adults With and Without Cancer and/or ASCVD, From the National Health

Interview Survey, 2013 to 2018

Neither ASCVD Nor Cancer

Cancer Only

ASCVD Only

Both ASCVD
and Cancer

Reference

1.12 (1.05–1.20)

1.90 (1.77–2.03)

1.93 (1.63–2.28)

1.12 (1.04–1.21)

1.35 (1.25–1.47)

1.39 (1.14–1.69)

Any ﬁnancial toxicity*
Model 1
Model 2
Any difﬁculty paying medical bills
Model 1

Reference

Model 2

1.36 (1.27–1.45)

2.04 (1.91–2.19)

2.27 (1.91–2.70)

1.29 (1.20–1.39)

1.53 (1.41–1.65)

1.54 (1.27–1.86)

Unable to pay medical bills
Model 1

Reference

Model 2

1.27 (1.12–1.45)

2.52 (2.30–2.76)

3.43 (2.83–4.16)

1.29 (1.11–1.50)

1.54 (1.38–1.71)

2.02 (1.59–2.57)

High ﬁnancial distress
Model 1

Reference

Model 2

1.15 (1.07–1.24)

2.04 (1.90–2.18)

2.46 (2.08–2.92)

1.03 (0.95–1.12)

1.13 (1.04–1.24)

1.26 (1.03–1.55)

1.78 (1.62–1.96)

3.22 (2.93–3.54)

4.72 (3.86–5.78)

1.17 (1.04–1.31)

1.48 (1.32–1.67)

1.63 (1.27–2.09)

0.95 (0.86–1.05)

2.65 (2.45–2.87)

3.19 (2.65–3.83)

0.95 (0.84–1.07)

1.27 (1.14–1.42)

1.34 (1.05–1.69)

1.33 (1.21–1.45)

2.08 (1.92–2.25)

2.51 (2.08–3.03)

1.14 (1.02–1.26)

1.32 (1.18–1.47)

1.61 (1.28–2.03)

Cost-related medication nonadherence
Model 1

Reference

Model 2
Food insecurity
Model 1

Reference

Model 2
Foregone/delayed care due to cost
Model 1

Reference

Model 2

Values are odds ratio (95% conﬁdence interval). *Any difﬁculty paying medical bills  high ﬁnancial distress  cost-related medication non-adherence  food insecurity 
delayed/foregone care due to cost. Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity, family income, education, insurance type, geographic region, cardiovascular risk factor proﬁle, comorbidities, and, where appropriate (high ﬁnancial distress, cost-related medication nonadherence, food insecurity and foregone/delayed care
due to cost), burden from medical bills.
Abbreviations as in Table 1.

frequently reported cancers included breast, prostate,

addition, we also performed analyses including

and skin (unknown kind). Similar patterns were

breast, lung, and colorectal cancer only within our

observed in the population that reported both ASCVD

cancer group (i.e., no other cancer diagnoses were

and cancer (Supplemental Table 2).

included), given their high incidence and mortality.

Prevalence of FT measures by underlying condition

among

elderly

adults

are

described

in

Moreover, given concerns of having varying lengths
of time and survival for different cancers and in-

Supplemental Figure 1. Overall, the same pattern was

dividuals, we performed 2 additional analyses: ﬁrst,

observed for all FT measures as seen with non-elderly

a comparison including only those with an active

adults, although at signiﬁcantly lower proportions.

cancer diagnosis (i.e., only those with a cancer

Individuals reporting ASCVD with or without cancer

diagnosis diagnosed within the past year were

had a higher degree of difﬁculty paying medical bills,

included); and second, a series of stratiﬁed analyses

inability to pay at all, high ﬁnancial distress, cost-

by time since cancer diagnosis ($0 to #5, >5 to #15,

related medication nonadherence, food insecurity,

and >15 years). Overall, the patterns for FT mea-

and delayed/foregone medical care due to cost

sures remained similar in magnitude and direction

(Supplemental Figure 1). After adjusting for estab-

among both non-elderly and elderly adults when

lished confounders, presence of ASCVD was associ-

comparing

ated with a signiﬁcantly higher odds of any difﬁculty

Figures 2 to 13).

cancer

and/or

ASCVD

(Supplemental

paying medical bills and being unable of paying them
at all when compared with those without ASCVD or

DISCUSSION

cancer (Supplemental Table 4).
SENSITIVITY ANALYSES. Given the high prevalence

In a nationally representative study using data from

of nonmelanomatous skin cancer, we performed

2013 to 2018, we found that among non-elderly

similar

adults,

analyses

excluding

this

diagnosis.

In

ASCVD

was

associated

with

higher
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proportions of overall FT than patients with cancer,
and patients with both illnesses concurrently had the
worst outcomes across different measures of FT.

Financial Toxicity Among ASCVD/Cancer

F I G U R E 1 Distribution of Total Burden From Financial Toxicity Measures, by ASCVD

and/or Cancer Status, Among Non-Elderly Adults, From the National Health
Interview Survey, 2013 to 2018

These results were observed among elderly adults as
well, although at signiﬁcantly lower proportions.
These ﬁndings demonstrate the severity of FT in patients with ASCVD when compared with cancer, the
latter being one of the most researched causes of FT
in the current published medical literature (3,4,7).
Our ﬁndings extend the prior published literature
in several ways. First, to our knowledge, this is the
ﬁrst study directly analyzing FT in patients with
cancer versus patients with ASCVD. Prior studies have
suggested that the effect of ASCVD on FT is likely
equivalent to or greater than that of cancer, but this
issue had not been deﬁnitively investigated (34,35).
In a previous paper, Narang et al. (34) detailed the
differences in Medicare beneﬁciaries with cancer
(compared with those without cancer, and sub-

FT measures: any difﬁculty paying medical bills  high ﬁnancial distress  cost-related
medication non-adherence  food insecurity  delayed/foregone care due to cost.

stratiﬁed by other comorbidities), their out-of-pocket

ASCVD ¼ atherosclerotic cardiovascular disease; FT ¼ ﬁnancial toxicity; NHIS ¼ National

(OOP) expenditures, and ﬁnancial burden. They

Health Interview Survey.

showed that individuals with heart disease and/or
stroke had higher median OOP expenditures ($2,371
vs. $2,120; p < 0.05) and ﬁnancial burden (7.0% vs.
5.7%; p < 0.05) when compared with those with

Although understudied, our results build on the cur-

cancer in the overall study population. Our results

rent published data regarding individuals with

not only conﬁrm that individuals with a diagnosis of

ASCVD as also having a high degree of the ill-

cancer have higher odds of all measures of FT than

associated measures under the umbrella of FT

those without cancer nor ASCVD, but also highlight

(12,13,35).

the burden that ASCVD represents in the overall adult

Our ﬁndings highlight the prevalence of, and ur-

population. Second, our study highlights the degree

gent need for, effective methods to alleviate FT for

to which patients with these diseases experience

ASCVD and cancer patients. In the current health

ﬁnancial health-related consequences. Furthermore,

system climate, there are small- and large-scale

we also broaden the scope of the FT phenomenon

strategies to identify and combat FT. Clinicians can

across all adults, non-elderly and elderly. Our main

help patients deal with FT, as observed among on-

study population was non-elderly adults, given that

cologists when prompted to talk to their patients

this population tends to have higher FT overall (5).

about ﬁnancial burden in the ofﬁce (38). This may be

Interestingly, we found that ASCVD was associated

especially important for physicians, nurses, and

with a higher prevalence of FT, both alone and when

advanced practice providers who care for patients

occurring concurrently with cancer, compared with

with ASCVD and/or cancer, given the high economic

patients with cancer, including the elderly popula-

burden and morbimortality potential these diseases

tion. Based on previous reports, the drivers of FT,

carry. Indeed, it has been reported that a majority of

however, may be different in these populations; FT in

patients with FT-related issues would like to discuss

cancer usually stems from cancer therapy pharma-

this problem with their health care providers; how-

ceutical pricing (36), whereas ASCVD tends to be

ever, reports indicate that discussions addressing

related to acute events often requiring hospitaliza-

these concerns happen approximately in one-third of

tion, like myocardial infarctions and/or stroke (13).

encounters (39) and are often not addressed at all

FT in cancer has been well described (3,5). Our

(40–42). There are tools available for clinicians to

results align with previous studies that found in-

address this problem. One such validated tool to

dividuals with cancer to have high ﬁnancial distress,

engage with patients and test for FT is the COmpre-

cost-related medication nonadherence, food insecu-

hensive Score for ﬁnancial Toxicity (COST), a patient-

rity, and foregone/delayed care overall (10,23,37).

reported outcome measure to gauge FT in patients
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with cancer, which has been validated in the United

relating to ﬁnancial hardship used in NHIS assessed

States and abroad (43–45). However, to our knowl-

not only whether an individual but also whether

edge, there are currently no tools for clinicians to

anyone in the household had ﬁnancial hardship, and

measure FT among patients with ASCVD. Given the

precludes assessment of the proportion of medical

promise shown by COST, future work should develop

bills directly related to ASCVD and/or cancer and

and validate tools similar to COST for ASCVD pa-

their contribution to ﬁnancial hardship itself. Khera

tients. Such assessments leveraged proactively (e.g.,

et al. (13) recently detailed that health care spending

during annual check-ups) combined with patient

on family members with ASCVD represented a mean

education on the costs involved in treatment of

of 70% of the overall family OOP health spending,

chronic cardiovascular conditions may persuade pa-

with the respective proportion being slightly higher

tients to adopt healthier lifestyles that effectively

for low-income families. Fourth, it was not possible

avoid potential FT. For this reason, the American

to differentiate the proportion of ﬁnancial hardship

Heart Association and the American College of Car-

caused by a speciﬁc catastrophic event from the ef-

diology will likely incorporate value and cost in their

fect of chronic bills. A recent survey suggested that

next guidelines (46). However, as a strong research

over 60% of individuals with ﬁnancial hardship from

ﬁeld in medications, devices, and innovation, cardi-

medical bills reported it being tied to a catastrophic

ology clinicians are lagging behind in terms of FT in

medical expense, whereas 1 reports bills for treat-

an era where treatment permits longer survival for

ment of chronic conditions that have built up over

their patients. This is paramount due to patients with

time (54). Fifth, it is difﬁcult to establish causality

cancer and/or ASCVD living longer lives through

due to the cross-sectional nature of this study. It is

better and earlier care—which in parallel increases

possible that there is a bidirectional relationship

the potential for FT. Even with an aging population,

between FT and some of its perceived effects on

which by deﬁnition has higher risk for both diseases

ASCVD and/or cancer. For example, it has been

and access to universal health coverage, Medicare

described that food insecurity is often more preva-

patients appear to have lower FT, but are still not

lent in the low-income population (55–57), hinting

exempt from it (34,47); this population would ulti-

toward an income-based problem rather than a

mately have to deal with problems of a different na-

purely

ture altogether, like caregiver distress and end-of-life

Although is it plausible that causality may be bidi-

care and costs. We hope that by describing the extent

rectional (i.e., food insecurity could lead to inade-

health-related

ﬁnancial

ﬁnancial

consequence.

ﬁnancial

of FT in patients with ASCVD, cancer, or both, clini-

quate

cians will not only be able to provide better care, but

hardship could lead to food insecurity) (57), others

will also be able develop support structures and in-

have argued that health behaviors could potentially

terventions for the patients experiencing these dis-

be affected by food insecurity (58). Sixth, no ad-

eases and FT (48).

justments for possible type 1 errors for multiple

STUDY LIMITATIONS. First, our study population—

comparisons were used, so these results should be

those with ASCVD and/or cancer—was based on self-

interpreted with caution. Finally, there is a possi-

report. Although self-reported conditions can be

bility that the strategies to mitigate FT in cancer

potentially inaccurate, our estimates agree with

have started yielding positive results, and these are

those from previous published data using NHIS

reﬂected in our analyses.

(12,49,50), and are in line with those reported by

CONCLUSIONS

coping

behaviors,

or

national associations, like the American Heart Association and the Centers for Disease Control and

Patients with ASCVD report greater difﬁculty paying

Prevention (51,52). Second, we evaluate a limited

bills and experience high ﬁnancial distress from

number of features of FT from health care. Other

medical

aspects of ﬁnancial ill-effects of treatments may not

adherence, and food insecurity, and they forego/

be captured. However, our focus was on domains

delay care due to cost at a proportion exceeding those

that have been validated and widely used in prior

with the population with cancer. It is critical that

studies and have shown to correlate well with

interventions to mitigate treatment-related costs that

objective measures of ﬁnancial burden from OOP

have been implemented among cancer patients are

costs for medical expenditures (53). Third, questions

evaluated for patients with ASCVD. Finally, we hope

costs,

cost-related

medication

non-
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that the ﬁndings documented here would serve as
the basis for future prospective patient-centered in-

ADDRESS FOR CORRESPONDENCE: Dr. Khurram

quiries to investigate patients’ perceptions of FT

Nasir, Division of Cardiovascular Prevention and

to

Wellness, Houston Methodist DeBakey Heart and

inform

well-accepted

and

sustainable

Vascular Center, Center for Outcomes Research,

interventions.
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